172 related articles for article (PubMed ID: 17541035)
1. The peroxisome proliferator-activated receptor-gamma agonist troglitazone inhibits transforming growth factor-beta-mediated glioma cell migration and brain invasion.
Coras R; Hölsken A; Seufert S; Hauke J; Eyüpoglu IY; Reichel M; Tränkle C; Siebzehnrübl FA; Buslei R; Blümcke I; Hahnen E
Mol Cancer Ther; 2007 Jun; 6(6):1745-54. PubMed ID: 17541035
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor γ agonist pioglitazone inhibits β-catenin-mediated glioma cell growth and invasion.
Wan Z; Shi W; Shao B; Shi J; Shen A; Ma Y; Chen J; Lan Q
Mol Cell Biochem; 2011 Mar; 349(1-2):1-10. PubMed ID: 21221726
[TBL] [Abstract][Full Text] [Related]
3. A peroxisome proliferator-activated receptor-gamma agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B on human glioma cells.
Akasaki Y; Liu G; Matundan HH; Ng H; Yuan X; Zeng Z; Black KL; Yu JS
J Biol Chem; 2006 Mar; 281(10):6165-74. PubMed ID: 16319070
[TBL] [Abstract][Full Text] [Related]
4. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta.
Kawai T; Masaki T; Doi S; Arakawa T; Yokoyama Y; Doi T; Kohno N; Yorioka N
Lab Invest; 2009 Jan; 89(1):47-58. PubMed ID: 19002105
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonist inhibits transforming growth factor-beta1 and matrix production in human dermal fibroblasts.
Zhang GY; Cheng T; Zheng MH; Yi CG; Pan H; Li ZJ; Chen XL; Yu Q; Jiang LF; Zhou FY; Li XY; Yang JQ; Chu TG; Gao WY
J Plast Reconstr Aesthet Surg; 2010 Jul; 63(7):1209-16. PubMed ID: 19617014
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone inhibits synthesis of transforming growth factor-beta1 and reduces matrix production in human peritoneal mesothelial cells.
Peng Y; Liu H; Liu F; Liu Y; Li J; Chen X
Nephrology (Carlton); 2006 Dec; 11(6):516-23. PubMed ID: 17199790
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against nondiabetic glomerulosclerosis in rats.
Ma LJ; Marcantoni C; Linton MF; Fazio S; Fogo AB
Kidney Int; 2001 May; 59(5):1899-910. PubMed ID: 11318962
[TBL] [Abstract][Full Text] [Related]
8. Effect of troglitazone on tumor necrosis factor alpha and transforming growth factor beta expression and action in human adipocyte precursor cells in primary culture.
Skurk T; Birgel M; Lee YM; Hauner H
Metabolism; 2006 Mar; 55(3):309-16. PubMed ID: 16483873
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone in combination with cisplatin against malignant pleural mesothelioma cell growth.
Hamaguchi N; Hamada H; Miyoshi S; Irifune K; Ito R; Miyazaki T; Higaki J
Cancer Sci; 2010 Sep; 101(9):1955-64. PubMed ID: 20608936
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor gamma agonist treatment.
Grommes C; Landreth GE; Sastre M; Beck M; Feinstein DL; Jacobs AH; Schlegel U; Heneka MT
Mol Pharmacol; 2006 Nov; 70(5):1524-33. PubMed ID: 16887936
[TBL] [Abstract][Full Text] [Related]
11. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
Yang CC; Wang YC; Wei S; Lin LF; Chen CS; Lee CC; Lin CC; Chen CS
Cancer Res; 2007 Apr; 67(7):3229-38. PubMed ID: 17409431
[TBL] [Abstract][Full Text] [Related]
13. Ciglitazone induces caspase-independent apoptosis through down-regulation of XIAP and survivin in human glioma cells.
Kang DW; Choi CH; Park JY; Kang SK; Kim YK
Neurochem Res; 2008 Mar; 33(3):551-61. PubMed ID: 17940898
[TBL] [Abstract][Full Text] [Related]
14. Troglitazone suppresses transforming growth factor-beta1-induced collagen type I expression in keloid fibroblasts.
Zhang GY; Yi CG; Li X; Ma B; Li ZJ; Chen XL; Guo SZ; Gao WY
Br J Dermatol; 2009 Apr; 160(4):762-70. PubMed ID: 19120328
[TBL] [Abstract][Full Text] [Related]
15. [Inhibitive effect of troglitazone on TGF-beta(1) and fibronectin expression in human peritoneal mesothelial cells].
Liu H; Peng YM; Liu FY; Liu YH; Li LY; Li J; Chen X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Jun; 32(3):473-9. PubMed ID: 17611328
[TBL] [Abstract][Full Text] [Related]
16. Regulation of dectin-1-mediated dendritic cell activation by peroxisome proliferator-activated receptor-gamma ligand troglitazone.
Kock G; Bringmann A; Held SA; Daecke S; Heine A; Brossart P
Blood; 2011 Mar; 117(13):3569-74. PubMed ID: 21296999
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone stimulates beta-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor.
Tilley DG; Nguyen AD; Rockman HA
Biochem Biophys Res Commun; 2010 Jun; 396(4):921-6. PubMed ID: 20460106
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor (PPAR)-gamma expression in human vascular smooth muscle cells: inhibition of growth, migration, and c-fos expression by the peroxisome proliferator-activated receptor (PPAR)-gamma activator troglitazone.
Benson S; Wu J; Padmanabhan S; Kurtz TW; Pershadsingh HA
Am J Hypertens; 2000 Jan; 13(1 Pt 1):74-82. PubMed ID: 10678274
[TBL] [Abstract][Full Text] [Related]
19. Keratinocyte-derived vascular endothelial growth factor biosynthesis represents a pleiotropic side effect of peroxisome proliferator-activated receptor-gamma agonist troglitazone but not rosiglitazone and involves activation of p38 mitogen-activated protein kinase: implications for diabetes-impaired skin repair.
Schiefelbein D; Seitz O; Goren I; Dissmann JP; Schmidt H; Bachmann M; Sader R; Geisslinger G; Pfeilschifter J; Frank S
Mol Pharmacol; 2008 Oct; 74(4):952-63. PubMed ID: 18599600
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor-gamma ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration.
Goetze S; Kintscher U; Kim S; Meehan WP; Kaneshiro K; Collins AR; Fleck E; Hsueh WA; Law RE
J Cardiovasc Pharmacol; 2001 Dec; 38(6):909-21. PubMed ID: 11707695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
